Generation of cytotoxic effector lymphocytes by MLTC using tumor cells genetically modified to secrete interleukin-2.

Yoshiyuki Yamaguchi(Hiroshima University), Tetsuya Toge(Hiroshima University), Katsuhiko Shimizu(Kawasaki Medical School), Koji Ohta(Hiroshima University), Kosuke Noma, Jun Hihara(Hiroshima University), Kazuhito Minami(Matsuyama Red Cross Hospital)
PubMed
May 10, 2001
Cited by 3

Related Papers

Current status of the molecular mechanisms of anticancer drug-induced apoptosis
|Cancer Chemotherapy and Pharmacology|2002|255
The role of Fas ligand and transforming growth factor β in tumor progression
|Cancer|2004|135
Targeted therapy against Bcl-2-related proteins in breast cancer cells
|Breast Cancer Research|2005|114
Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice
|International Journal of Cancer|1992|111
Therapeutic potential of antisense Bcl‐2 as a chemosensitizer for cancer therapy
|Cancer|2004|110